Interpreting a Negative Trial: Mesh Augmentation for Anterior Prolapse
You are asked to appraise a randomized trial of anterior colporrhaphy with versus without a biologic graft in 200 women with anterior prolapse. The primary outcome is anatomic recurrence (POP-Q Ba ≥ +1) at 12 months. Results: recurrence 38% with graft vs 42% without (RR 0.90, 95% CI 0.65–1.25, p = 0.53). There were more graft-related adverse events (erosion, dyspareunia) in the graft arm. The authors conclude the graft 'is not superior to native tissue repair.' A colleague says this proves grafts don't work.
1. Critique the trial's conclusion and the colleague's interpretation. What are the key threats to validity and how would you frame the result?
Read the worked answer
Key points:
- Absence of evidence is not evidence of absence. The CI (0.65–1.25) includes a clinically meaningful benefit (up to 35% relative reduction) as well as harm. The trial is underpowered to exclude a modest benefit; the conclusion should be 'no demonstrated benefit,' not 'no benefit.'
- Outcome choice: anatomic recurrence (Ba ≥ +1) is a surrogate; it does not capture symptoms, bother, reoperation, or quality of life. A trial powered on anatomic recurrence may miss patient-important differences.
- Follow-up: 12 months is short for prolapse; recurrence rates rise over time. Durability is the main claimed advantage of grafts, so a 12-month endpoint may be inadequate.
- Graft type: 'biologic graft' is heterogeneous - porcine dermis, fascia lata, etc. Results may not generalize across materials, and biologic grafts resorb and may not provide durable support.
- Adverse events: more erosion and dyspareunia in the graft arm is a real harm that must be weighed; even a small benefit may not justify added morbidity.
- Generalizability: single center? surgeon experience? population?
Framing: The trial supports that this biologic graft, at 12 months, did not improve anatomic outcomes and added adverse events. It does not establish that all grafts (or synthetic mesh) are ineffective, nor that a benefit is impossible. Shared decision-making should reflect uncertainty and the known harms.
2. How would you apply this evidence to a 55-year-old woman with recurrent anterior prolapse who asks about graft use?
Read the worked answer
- Acknowledge that evidence for biologic grafts in anterior repair is weak and that this trial did not show benefit at 12 months while showing more adverse events.
- For recurrent anterior prolapse, native tissue repair has meaningful recurrence rates; some surgeons use synthetic mesh or biologic grafts, but evidence is limited. The FDA has cautioned about transvaginal mesh for prolapse; synthetic mesh use should be reserved for specific situations and discussed explicitly.
- Discuss alternatives: sacrocolpopexy with anterior extension (if apical component), pessary, or native tissue repair with the understanding of recurrence risk.
- Emphasize patient goals: durability vs. risk of dyspareunia and erosion, especially if she is sexually active.
- Document informed consent reflecting uncertainty.
I would not tell her 'grafts don't work'; I would say the evidence is insufficient to recommend a biologic graft routinely, and that the choice depends on her priorities and anatomy.